Primary sclerosing cholangitis (PSC) is a long-term progressive liver disease characterized by inflammation and scarring of the bile ducts that causes them to narrow. This leads to a build-up of bile and liver damage over time. The main symptoms include itching, jaundice and fatty stool. PSC often occurs with inflammatory bowel disease and patients may require liver transplantation if it progresses to end-stage liver disease.
The primary factors driving the growth of the primary sclerosing cholangitis market include rising incidence and prevalence of inflammatory bowel diseases like ulcerative colitis which increases the risk of PSC by 10-15 times. In addition, the development and approval of novel drugs to treat PSC such as obeticholic acid in May 2022 is expected to boost the market growth. However, lack of approved drugs and limited treatment options continue to restrain the market to some extent.
Market key trends:
Primary Sclerosing Cholangitis (PSC) is a chronic progressive disease that affects the bile ducts in the liver. The key trends in the PSC market include increased adoption of ursodeoxycholic acid medications and combination therapies for the disease management. Ursodeoxycholic acid continues to be the first line of treatment for PSC, though its efficacy is limited. There is an increase in pipeline drugs in combination with ursodeoxycholic acid that aim to improve treatment outcomes.
Strengths: Growing research and development activities for improved treatment options.
Weaknesses: No FDA approved drug offers cure and existing medications only manage symptoms.
Opportunities: High unmet need in the market provides scope for novel drugs and combination therapies.
Threats: Stringent regulations for drug approval and high costs associated with clinical trials.
Global Primary Sclerosing Cholangitis Market Size is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing research in developing novel drugs for PSC.
The global PSC market size in 2022 is estimated to be US$ 3,604.7 Mn. North America dominates the global PSC market currently due to growing prevalence of IBD in the region and availability of advanced healthcare facilities.
North America leads with the highest market share currently due to growing prevalence of IBD disorders leading to PSC in the region along with availability of advanced healthcare facilities. The Asia Pacific region is anticipated to exhibit fastest growth over the forecast period owing to rising healthcare expenditure and increased awareness regarding PSC.
Key players operating in the Primary Sclerosing Cholangitis market are Mirum Pharmaceuticals, Intercept Pharmaceuticals, CymaBay Therapeutics, Dr. Falk Pharma GmbH, and Gilead Sciences.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it